gilead sciences hiv - Search News

News

FDA Approves Gilead’s HIV Shot. It Works 99.9% of Time.

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who received it in large clinical trials. The drug, developed by Gilead Sciences and called Yeztugo,

USA TODAY on MSN · 19h

FDA approves new twice-yearly HIV shot. What to know

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

ConsumerAffairs · 1h

FDA approves twice-yearly injection for HIV prevention

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Pa

The Independent1h

UNAIDS urges Gilead to drop price of new HIV prevention drug

The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...

The BMJ37m

“Hard to justify” $28 000 price tag for breakthrough HIV prevention treatment, says UN agency

A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...

Pharmabiz8h

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

Should You Buy Gilead Stock At $110?

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

CSRWire1d

Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award

Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results